Video

CLL: Venetoclax in the R/R Setting

Author(s):

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
David C. Fisher, MD
David C. Fisher, MD
Nitin Jain, MD
Kathleen A. Dorritie, MD
Alexey Danilov, MD, PhD
John Seymour, MBBS, FRACP, PhD
A panel of 5 experts on CLL
Related Content
CLL, Image credit: LASZLO– stock.adobe.com
November 20th 2024

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

Matthew Cortese, MD, MPH, assistant professor, oncology, Department of Medicine-Lymphoma, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center
November 6th 2024

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024